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Abstract
Background: miRNAs are small noncoding RNA molecules that play an important role in post-transcriptional
regulation of gene expression. Length and/or sequence variants of the same miRNA are termed isomiRs. While
most isomiRs are functionally redundant compared to their canonical counterparts, the so-called 5’isomiRs exhibit a
shifted 5’ end and therefore a shifted seed sequence resulting in a different target spectrum. However, not much is
known about the functional relevance of these isoforms.
Results: Analysis of miRNA-seq data from breast cancer cell lines identified six pairs of highly expressed miRNAs
and associated 5’isomiRs. Among them, hsa-miR-140-3p was of particular interest because its 5’isomiR showed
higher expression compared to the canonical miRNA annotated in miRbase. This miRNA has previously been shown
to control stemness of breast cancer cells. miRNAseq data of breast cancer patients (TCGA dataset) showed that
both the canonical hsa-miR-140-3p and its 5’isomiR-140-3p were highly expressed in patients’ tumors compared to
normal breast tissue. In the current work, we present the functional characterization of 5’isomiR-140-3p and the
cellular phenotypes associated with its overexpression in MCF10A, MDA-MB-468 and MDA-MB-231 cell lines in
comparison to the canonical hsa-miR-140-3p. Contrary to the effect of the canonical hsa-miR-140-3p,
overexpression of the 5’isomiR-140-3p led to a decrease in cell viability. The latter observation was supported by
cell cycle analysis, where the 5’isomiR-140-3p but not the hsa-miR-140-3p caused cell cycle arrest in G0/G1-phase.
Additionally, 5’ismoiR-140-3p overexpression was found to cause a decrease in cell migration in the three cell lines.
We identified three novel direct target genes of the 5’isomiR-140-3p; COL4A1, ITGA6 and MARCKSL1. Finally, we have
shown that knocking down these genes partially phenocopied the effects of the 5’isomiR-140-4p overexpression,
where COL4A1 and ITGA6 knockdown led to reduced cell viability and cell cycle arrest, while MARCKSL1 knockdown
resulted in a decrease in the migratory potential of cells.
Conclusions: In summary, this work presents evidence that there is functional synergy between the canonical hsa-
miR-140-3p and the newly identified 5’isomiR-140-3p in suppressing growth and progression of breast cancer by
simultaneously targeting genes related to differentiation, proliferation, and migration.
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Background
Breast cancer is a complex heterogeneous form of can-
cer with lots of genetic alterations. According to the
American Cancer Society, excluding the cancers of skin,
breast cancer is the most common cancer among
women, accounting for nearly one in three cancers diag-
nosed in US women [1]. In breast cancer, it is not the
primary tumor, but its metastases at different distant
sites that are the main cause of death [2]. Based on dif-
ferent phenotypes and gene expression profiling, breast
cancer can be divided into five major so-called PAM50
subtypes: luminal A, luminal B, tumor enriched with hu-
man epidermal growth factor receptor 2 (Her2), basal-
like and normal-like subtype [3–6]. Luminal subtypes
are characterized by the expression of estrogen receptor
(ER) and are treated with adjuvant endocrine therapy
targeting the ER signaling such as tamoxifen and aro-
matase inhibitors [6]. The third subtype, Her2 positive,
is classified by the absence of ER and progesterone re-
ceptor (PR) expression, high expression of Her2 and
high proliferation rate [6]. Her2 positive tumors can be
targeted using an antibody against Her2 such as trastu-
zumab [7, 8]. Basal-like breast cancer generally ex-
presses none of the three markers (ER, PR and Her2),
and largely corresponds to the group of triple negative
breast cancer (TNBC). It is often highly aggressive and
is associated with poor prognosis [9]. No targeted ther-
apies are currently available for this breast cancer sub-
type and current regimes include the conventional
chemotherapeutic approach. Nevertheless, promising
strategies are being developed to treat TNBC, such as
poly-ADP ribose polymerase-1 inhibitors [6, 10, 11].
Normal-like subtype is the rarest form of breast cancer. It
is relatively poorly characterized, yet has been shown to
express ER, Her2 and PR. Its clinical prognosis is believed
to lie between TNBC and luminal A subtypes [6].
MicroRNAs (miRNAs) are single stranded RNA mole-
cules of ~22 nucleotides that are associated with the
Argonaute proteins (AGO). They serve a role in post-
transcriptional gene regulation in both plants and ani-
mals. miRNAs are generated by the sequential action of
two RNase III-type proteins (Drosha and Dicer) on short
hairpin RNAs. Upon cleavage by Dicer, the small RNA
duplex is incorporated into a complex known as RNA-
induced silencing complex (RISC) or in case of miRNAs
referred to as miRISC [12–14].
miRNAs control most of the protein-coding genes
resulting in control of cancer-relevant processes such as
cell cycle, proliferation, differentiation, apoptosis, and
migration. miRNAs associated with cancers are termed
oncomiRs. A single miRNA can target hundreds of
mRNAs. Hence, even though the regulation of gene ex-
pression by miRNAs is generally rather mild, aberrant
expression of a single miRNA may affect a multitude of
transcripts involved in cancer-related signaling path-
ways. This fact makes the situation more complex, as
the overall functions of miRNAs in oncogenesis can be
context dependent. Accordingly, a particular miRNA
may be found to be upregulated in some cancers while
being downregulated in others [15]. These findings be-
came more pronounced with the availability of whole
genome mRNA and miRNA expression data from dif-
ferent cancers [16–20]. In addition, mouse models with
miRNA overexpression or ablation have shown a direct
causal link between miRNA expression profiles and cancer
development. Clinically, miRNA are studied as clinical
biomarkers and/or putative therapeutic targets [21, 22].
Deep sequencing technologies have enabled the more
extensive study of miRNAs, leading to the identification
of different variants of the same miRNA. Typically,
miRNAs are annotated as a single defined sequence
and despite that, for many miRNAs, length and/or se-
quence variants have been observed, these variants
were believed to be experimental artefacts and were
thus ignored or dismissed [23]. However, massive paral-
lel sequencing and computational algorithms have con-
firmed the biological existence of such variants in
different species [24, 25]. The term isomiR was coined
to describe the different sequence and/or length vari-
ants of an individual miRNA. Additionally, studies
demonstrated the active associations between isomiRs
and RISC, suggesting that they can interact with
mRNAs [26]. These observations pointed to the pos-
sible physiological role of isomiRs. Different reports
pointed to gender and/or race dependence of the iso-
miRs expression [27, 28]. However, the regulatory mecha-
nisms underlying the production of specific isomiRs are
not fully understood. Moreover, to date, there have been
only few reports on the functional role of lowly abundant
5’isomiRs and the capacity to modulate their targets rela-
tive to the canonical counterparts [28, 29]. However, the
functional importance of highly expressed 5’isomiRs has
not been addressed, yet.
Generally, isomiRs can broadly be classified into three
main categories: 5’ isomiRs, 3’ isomiRs and polymorphic
isomiRs. 3’ and 5’ isomiRs are those having variations at
the 3’ and 5’ ends of the mature miRNA sequence re-
spectively, whereas polymorphic isomiRs are harboring
different internal nucleotide sequences [23]. Different
mechanisms contribute to the generation of isomiRs. In
the canonical miRNA biogenesis pathway 5’ and 3’ ends
are specified by consecutive cleavage events of the pri-
mary transcript by the ribonucleases Drosha and Dicer.
The alternative cleavage by Drosha and/or Dicer could
result in length variation which has been shown to par-
tially depend on individual features such as ethnical
background [27, 28, 30]. Furthermore, the 3’ ends of
the RISC-bound miRNAs are liable to trimming by
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exoribonucleases [31, 32]. In the latter two cases the
product is termed “templated”, since the miRNA se-
quence still matches the parent gene. Post-transcriptional
addition of one or more bases might also take place with
the help of nucleotidyltransferases. Most of the nucleoti-
dyltransferases are 5’- 3’ polymerases leading to the forma-
tion of 3’ isomiRs [33]. The addition of nucleotides that
do not match the parent gene is termed as “non-tem-
plated” addition [34]. RNA editing, especially adenosine to
inosine editing (A-to-I) is suggested to be a major driver
in the generation of polymorphic isomiRs [35]. Most miR-
NAs, however, do not exhibit a high frequency of editing.
The most frequently observed type of isomiR in animals
and plants is the 3’ isomiR. 5’ and polymorphic isomiRs
are generally rare. Nevertheless, they still represent a sig-
nificant proportion of the population of some miRNAs
[36, 37]. 3’ isomiRs or non-seed-based nucleotide substitu-
tions are believed to be functionally redundant and mainly
affect miRNA stability. In contrast, it has been shown
that 5’ isomiRs can have different mRNA targets and
thereby different phenotypes compared to their canon-
ical counterparts [27, 28, 34].
MiR-140 is encoded within intron 16 of Wwp2, an E3
ubiquitin ligase. It was first identified as a key player in
cartilage development and homeostasis in chondrocytes
[38]. The regulation of miR-140 was reported to be
tissue-dependent. Besides its role in chondrocytes, it was
found to be expressed in numerous other tissues and cell
types including brain, breast, lung, colon, ovary and
testis [39–41]. Importantly, expression-profiling experi-
ments revealed a potential tumor suppressor function
for miR-140 in many cancers where its expression was
found to be downregulated in cutaneous squamous cell
carcinoma, basal cell carcinoma, osteosarcoma, ovarian
cancer, colon cancer and lung squamous cell carcinoma.
Inversely, Zou et al. revealed a correlation between miR-
140-3p overexpression with chordoma invasion and re-
currence suggesting poor prognosis [42].
In the majority of miRNA species, the 5’ miRNA is an-
notated as the guide strand, while the complimentary 3’
miRNA is degraded. Interestingly enough, stably expressed
levels of miR-140-3p as well as miR-140-5p were found to
be present. The expression was found to be tissue
dependent and each strand had its own function owing to
different seed sequences [43]. Wolfson et al. reported a
tumor suppressor role for miR-140 mediated by Wnt,
SOX2 and SOX9 stem cell regulator pathways [44].
Downregulation of miR-140 in breast cancer was attrib-
uted to methylation of CpG islands in the promoter region
of the miRNA gene. Inhibition of miR-140 allows for
uncontrolled elevation of SOX2, which is known to be
a stem cell self-renewal regulator causing an increase in
stem cell populations and breast cancer progression,
initiation and growth [44]. miR-140-3p is one of few
miRNAs that showed high expression of 5’isomiR ac-
cording to miRBase [45].
In the present work, we sought to characterize the ef-
fects of the overexpression of both the canonical hsa-
miR-140-3p and the 5’isomiR-140-3p on breast cell lines
through functional assays that assess cell viability, cell
cycle, apoptosis and migration. Moreover, we aimed at
identifying and validating target genes for 5’isomiR-
140-3p that could account for the observed phenotypes.
In summary, we could attribute tumor-suppressive phe-
notypes including reduced proliferation due to cell
cycle arrest in G0/G1 phase of the cell cycle as well as
reduced cell migration specifically to the 5’isomiR-140-
3p. These phenotypes could be linked to direct target-
ing of MARCKSL1, ITGA6 and COL4A1. Analysis of
two major breast cancer patient cohorts (METABRIC
and TCGA) confirmed the relevance of both miRNA
and the novel target genes, especially in TNBC.
Results
5’isomiR-140-3p is highly expressed in breast cancer cell
lines and patients
With the advent of miRNA sequencing, the existence of
isomiRs became increasingly clear. In addition, it is now
possible to quantitatively assess expression of miRNAs
and their isomiRs to allow for estimations of their bio-
logical relevance. Combining these two means of infor-
mation, we analyzed miRNA sequencing datasets of
several breast cancer cell lines that had been generated
as part of the Illumina iDEA challenge to identify pairs
of highly expressed miRNAs and 5’isomiRs. Here, we
neglected variants at the 3’end of both species, treating
all 3’isomiRs with a length of 18–24 nucleotides as
miRNA or 5’isomiR, respectively, depending on their 5’
end. Using the notation suggested by Loher and col-
leagues [27], we refer for example to all miRNA species
between hsa-miR-140-3p 0|-3 and 0|+3 (in Table 1 sim-
plified as 0|x) as canonical hsa-miR-140-3p, whereas all
species between hsa-miR-140-3p +1|-2 to +1|+3 (in
Table 1 simplified as +1|x) are considered as 5’isomiR-
140-3p. The sequencing data is provided as Additional
file 1 and the raw data as well as more detailed informa-
tion about the experimental setup can be found at
ArrayExpress (E-MTAB-4539).
As criteria, we defined an expression of the canonical
miRNA of at least 100 rpm on average and a ratio be-
tween 5’isomiR and miRNA of at least 1 to 5 on aver-
age. Thereby, we identified six potentially interesting
miRNA/5’isomiR pairs (Table 1). Interestingly, we
found that in case of one of these miRNAs, namely
miR-140-3p, expression of the isomiR was even higher
compared to the canonical form. Therefore, we decided
to focus on this pair.
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We analyzed the breast cancer patients’ sequencing
data from TCGA for the expression of the canonical
hsa-miR-140-3p and its 5’isomiR-140-3p [46]. The clin-
ical characteristics as well as the expression of canonical
miRNA and 5’isomiR are listed in Additional file 2. The
abundance of the different 3’isomiRs of the two 5’iso-
miRs under investigation is detailed in Additional file 3
listing the average expression of each miRNA species in
the analyzed patient samples.
Both isoforms were found to be strongly positively cor-
related (p < 0.001, r = 0.85; Fig. 1a). The patients from the
same dataset were grouped according to ER expression
and the levels of hsa-miR-140-3p and 5’isomiR-140-3p
were analyzed. It was found that both the hsa-miR-140-3p
and 5’isomiR-140-3p were higher in ER negative (ER-) pa-
tients (Fig. 1b). Furthermore, patients with distant metas-
tases had lower expression of both isoforms compared to
patients without metastases (Fig. 1c). Additionally, survival
analysis in TNBC patients showed a trend of better sur-
vival among patients with higher expression levels of both
hsa-miR-140-3p and 5’isomiR-140-3p (Fig. 1d); a trend
that was not observed when analyzing the overall popula-
tion of breast cancer patients (data not shown).
5’isomiR specifically inhibits proliferation and migration
of breast cell lines
In order to evaluate the biological significance of both
isoforms, we carried out a set of functional assays on
MCF10A, MDA-MB-231 and MDA-MB-468 cells. All
these cells are negative for ER, PR and HER2. MCF10A
cells are non-transformed cells with higher genomic sta-
bility and generally higher susceptibility to perturbations
of their normal growth and migratory behaviour when
compared to the TNBC cell lines MDA-MB-231 and
MDA-MB-468 that harbour more mutations. WST-1-
based cell viability assay was used to assess the effect of
overexpression of the canonical hsa-miR-140-3p and the
5’isomiR-140-3p on the cells in both cell lines. hsa-miR-
140-3p did not affect the cell viability as compared to
the mimic-miRNA negative controls. In contrast, 5’iso-
miR-140-3p caused a significant decrease in cell viability
in all three cell lines (Fig. 2a).
The effects of the hsa-miR-140-3p and 5’isomiR-140-
3p overexpression on the cell cycle were also tested.
MCF10A, MDA-MB-231 and MDA-MB-468 cells were
transfected with miRNA mimics, (Fig. 2b). In all three
cell lines, 5’isomiR-140-3p overexpression resulted in a
cell cycle arrest where more cells were found at the G0/G1
phase. Overexpression of the canonical hsa-miR-140-3p,
however, showed no pronounced effect on the cell cycle.
Analysis of baseline apoptosis in these cell lines showed
no elevated activity of caspase-3/7 in 5’isomiR overex-
pressing cells as determined by NucView-488 caspase-3/7
assay (Biotium, Hayward, CA, USA; data not shown).
In addition, we tested the impact of overexpression of
both isoforms on cell migration in a transwell-based cell
migration assay. Cell numbers were normalized to a seed-
ing control and are shown as relative values compared to
control transfected cells. A decrease in cell migration was
observed upon the overexpression of 5’isomiR-140-3p
relative to hsa-miR-140-3p or the negative control in all
three cell lines (Fig. 2c).
miR-140-3p and its 5’isomiR have overlapping but
different target spectra
The 5’isomiR is shifted by one nucleotide at the 5’ end
resulting in a different seed sequence, and thus is ex-
pected to have different target mRNAs. In order to
examine the different spectra of target genes of the ca-
nonical miRNA and the 5’isomiR, a gene expression
microarray was performed upon overexpression of both
hsa-miR-140-3p and 5’isomiR-140-3p in MCF10A as
well as MDA-MB-231 cells and respective negative con-
trols in two biological replicates. Genes were considered
Table 1 Expression (in rpm) of pairs of highly expressed miRNAs/5’isomiRs in a panel of breast cancer cell lines
Notation of isoform Seed sequence MCF7 MDA-MB-231 T47D BT20 BT474 MDA-MB-468 ZR-75 MCF10A
miR-10a-5p 0|x canonical ACCCTGT 81.9 4923.9 9254.5 7698.9 96.5 181.4 854.1 582.7
miR-10a-5p +1|x isomiR CCCTGTA 56.9 2158.4 3911.3 3660.0 64.2 65.0 477.0 273.0
miR-1307-3p 0|x canonical CTCGGCG 1159.2 737.2 2299.7 575.6 1894.2 554.8 2560.7 290.0
miR-1307-3p +1|x isomiR TCGGCGT 394.2 253.2 943.8 222.5 643.7 348.3 784.3 72.7
miR-140-3p 0|x canonical ACCACAG 180.9 486.8 117.4 289.0 149.1 63.0 181.2 199.2
miR-140-3p +1|x isomiR CCACAGG 407.7 851.6 284.8 568.7 217.6 95.2 306.2 332.8
miR-183-5p 0|x canonical ATGGCAC 1187.2 91.7 1065.9 1132.5 2017.2 1028.1 849.9 518.7
miR-183-5p +1|x isomiR TGGCACT 1102.0 44.0 831.3 822.5 1860.5 767.9 725.6 312.4
miR-203-3p 0|x canonical TGAAATG 2327.2 3.1 2514.6 544.1 5319.0 427.8 2870.3 71.3
miR-203-3p +1|x isomiR GAAATGT 2115.5 1.5 1137.8 329.8 2116.1 175.1 1104.8 23.1
miR-30a-3p 0|x canonical TTTCAGT 13.9 991.7 162.5 191.8 30.8 1033.2 108.8 239.7
miR-30a-3p +1|x isomiR TTCAGTC 3.7 305.1 53.5 65.8 6.6 311.7 35.8 44.1
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to be downregulated by either miRNA, when their ex-
pression was reduced by at least 35 % with a significant
corrected p-value in both cell lines. Interestingly, 109
genes were downregulated in both cell lines specifically
by 5’isomiR-140-3p, whereas 18 genes were downregu-
lated specifically in both cell lines by hsa-miR-140-3p
and 5 genes were downregulated by both (Fig. 3a and
Additional file 4). Of note, genes downregulated by ei-
ther miR-140-3p or 5’isomiR-140-3p were significantly
enriched for genes containing predicted target sites for
the respective miRNA species according to TargetScan
(see Additional file 5) [47].
Based on the results of the microarray analysis, we
aimed to identify genes targeted only by the 5’isomiR-
140-3p that might explain the tumor-suppressive pheno-
types observed upon overexpression of the 5’isomiR.
The 109 genes identified from the microarray were sub-
jected to literature research with the aim of defining
genes that might potentially phenocopy the viability, cell
cycle and migration phenotypes seen upon the overex-
pression of the 5’isomiR-140-3p. The 3’ UTRs of the
candidate target genes were analyzed for seed sequence
matches with the 5’isomiR-140-3p. Eight putative targets,
namely SRF, RUVBL1, MARCKSL1, CHCHD4, COL4A1,
Fig. 1 Statistical analysis of Breast Cancer patient data from TCGA [46]. Sequencing data from 616 patients were analyzed for miRNA expression levels
of the canonical hsa-miR-140-3p and the 5’ isomiR-140-3p. a Expression of the hsa-miR-140-3p and 5’isomiR-140-3p show strong positive correlation.
b hsa-miR-140-3p and 5’isomiR-140-3p levels are higher in ER- patients. c Distant metastases correlate with lower expression of both hsa-miR-140-3p
and 5’ isomiR-140-3p. d TNBC patients with high expression levels of hsa-miR-140-3p and 5’ isomiR-140-3p show a trend of better survival
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Fig. 2 (See legend on next page.)
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ITGA6, CAP1 and CCT5 met the aforementioned criteria.
The full length 3’UTRs of the target genes were cloned
into the dual luciferase reporter plasmid psiCHECK-2, a
vector that utilizes Renilla luciferase as the primary re-
porter gene (see Additional file 6 for primer sequences).
The respective reporter vectors or empty psiCHECK2
vector (as a negative control) were co-transfected with
hsa-miR-140-3p or 5’isomiR-140-3p or mimic miRNA
negative controls in MCF7 cells. Seventy-two hours post
transfection, relative luciferase activity (renilla luciferase
activity normalized to firefly luciferase activity) was mea-
sured (Fig. 3b). RLU values of target genes were normal-
ized to the RLU of the empty psiCHECK2 vector. We
identified the 3’ UTRs of MARCKSL1, CHCHD4, COL4A1
and ITGA6 to be specifically affected by 5’isomiR-140-3p.
Moreover, 3’ UTR of CCT5 showed a decrease in lucifer-
ase activity upon co-transfection with hsa-miR-140-3p
or 5’isomiR-140-3p, indicating targeting by both forms.
Therefore, it was excluded from further analyses. Add-
itionally, SRF and CAP1 were excluded from further ex-
periments since no reduction in luciferase activity was
observed compared to the empty vector.
In order to further confirm direct targeting of the can-
didate genes, miRNA-binding sites within the respective
3’UTRs were mutated and luciferase activity was mea-
sured. Values were normalized to the empty psiCHECK2
(Fig. 3c). Luciferase activity was rescued in all of the tar-
get genes but CHCHD4 (data not shown). This means
that the reduction observed in luciferase activity was po-
tentially due to an indirect effect. Therefore, CHCHD4
was omitted from further studies.
To validate downregulation of the putative target
genes on mRNA level, MCF10A and MDA-MB-231
cells were transfected with hsa-miR-140-3p, 5’isomiR-
140-3p or miRNA mimic negative control. The mRNA
expression levels of the candidate genes were then
assessed by Taqman qRT-PCR (Fig. 3d). Consistent
with the previous findings from microarray and lucifer-
ase assay, a reduction in the mRNA levels of the genes
ITGA6, MARCKSL1 and COL4A1 was observed.
In summary, ITGA6, MARCKSL1 and COL4A1 were
validated as direct targets of the 5’isomiR-140-3p and
further investigated for their impact on the phenotypes
observed upon overexpression of the 5’isomiR-140-3p.
COL4A1 encodes for collagen, type IV, alpha1.
MARCKSL1 encodes for a member of the myristoy-
lated alanine-rich C-kinase substrate (MARCKS) fam-
ily and ITGA6 encodes for the integrin subunit alpha 6
and is commonly found in heterodimers known as
α6β4 integrin and α6β1 integrin. Figure 4 highlights
the seed regions targeted by the 5’isomiR-140-3p in
the 3’UTR of each of the target genes. Nucleotides that
were mutated for the experiments shown in Fig. 3c are
highlighted.
Target gene knockdown partially phenocopies
overexpression of 5’isomiR-140-3p
Having identified and validated the targeting of several
candidate 3’UTRs, we attempted to link the downregu-
lated genes to the phenotypes observed upon the overex-
pression of the 5’isomiR-140-3p in MCF10A and/or
MDA-MB-231 cells. To this end, siRNAs were used to
knockdown candidate genes, and the effects on cell via-
bility, cell cycle and cell migration were assessed. We
used a set of 4 different siRNAs (numbered 1-4 accord-
ing to the order numbers assigned by the Dharmacon)
against each target gene. The knockdown efficiency of
each individual siRNA was assessed (Additional file 7).
In case of MARCKSL1, two siRNAs (MARCKSL1_3 and
MARCKSL1_4) were found to reduce the mRNA level.
In contrast, in case of COL4A1 and ITGA6, all four siR-
NAs were found to reduce its expression on the mRNA
level by 70 % or more. We continued further analyses
with COL4A1_2 and _4 and ITGA6_3 and _4.
Initially, the effect of candidate gene knockdown
on cell viability was evaluated. COL4A1 and ITGA6
knockdown was observed to phenocopy the effect of
5’isomiR-140-3p overexpression on cell viability in
both cell lines and for both siRNAs (Fig. 5a). The ef-
fect was not pronounced, yet was found to be
(See figure on previous page.)
Fig. 2 Effect of 5’ isomiR-140-3p overexpression on cell viability, cell cycle and cell migration. a and b MCF10A, MDA-MB-231 and MDA-MB-468
cells were transfected with miRNA mimics (hsa-miR-140-3p and 5’isomiR-140-3p), or mimic-ctrl2 (as negative control), then were incubated for
72 h. a WST-1 reagent was added to the cells and absorbance at 450 nm was measured. Results were normalized to the negative control. Data
are presented as average of 6 biological replicates ± standard deviation indicated as error bars. b MCF10A, MDA-MB-231 and MDA-MB-468 cells
were transfected with miRNA mimics, 24 h after transfection starved in serum-free media for 24 h and allowed to re-enter the cell cycle for 24 h
in full growth medium. Cells were incubated with BrdU for 30 min before fixation and lysis and stained with anti-BrdU-FITC and 7-AAD for subse-
quent FACS analysis. Data are presented as average and standard deviation of three biological replicates. c Cells were transfected in 6-well plates
with miRNA mimics (hsa-miR-140-p3 and 5’ isomiR-140-3p) or mimic miRNA negative control. 48 h later, cells were reseeded in transwell inserts
(with 8.0 μm polycarbonate membrane) in starvation medium. The lower well compartment had full growth medium to stimulate cell migration
across the insert membrane. After 20 h of migration, transwells were removed and cells were trypsinized from the lower surface of the membrane
and counted using flow cytometry (FACSCalibur, BD Biosciences). The absolute number of cells migrating was normalized to the total cell number
and values are presented as percentage of cells migrating. Values represent the average of 3 biological replicates ± standard deviation indicated
as error bars (*** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05 compared to control, unpaired t test)
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statistically significant relative to siRNA negative
control siAllstar. In contrast, MARCKSL1 knockdown
did not have any effect on cell viability.
Moving on to cell cycle analysis, effects of knockdown
of candidate target genes were examined. Only COL4A1
knockdown showed cell cycle arrest with a greater frac-
tion of cells in the G0/G1 phase and a reduction of the
percentage of cells in S phase in both cell lines, similar
to the 5’isomiR-140-3p (Fig 5b).
We proceeded next to examine the effect of candidate
gene knockdown on cell migration using a transwell-
based cell migration assay. We observed a significant de-
crease in cell migration upon the knockdown of
MARCKSL1 for both cell lines with both siRNAs. In
Fig. 3 Validation of direct targeting by 3’ UTR luciferase assay and Taqman qRT-PCR. a Venn diagram containing genes that were found to be
significantly downregulated in both MCF10A and MDA-MB-231 cells upon overexpression of has-miR-140-3p or 5’isomiR-140-3p to at least
65 % of the expression in control transfected cells. b and c MCF7 cells were transfected with the miRNA mimics and wildtype (b) or mutated
(c) psiCHECK2 3’ UTR reporter plasmids as indicated. 72 h later, cells were lysed and the activity of renilla (480 nm) and firefly (560 nm) luciferase
were measured. Renilla measurements were normalized to firefly and values were normalized to the negative control (mimic-ctrl2). Afterwards, values
were normalized to the empty psiCHECK2 transfected with 5’ isomiR-140-3p or hsa-miR-140-3p. Bars represent the average of 6 biological replicates ±
standard deviation indicated as error bars. d MCF10A and MDA-MB-231 cells were transfected with hsa-miR-140-3p, 5’ isomiR-140-3p or miRNA mimic
negative control (mimic-ctrl2). 72 h later, cells were lysed and total mRNA was isolated and purified using RNeasy kit (Qiagen). The mRNA expression
levels of the candidate genes were then assessed by Taqman qRT-PCR. Gene expression was normalized to HPRT and GAPDH housekeeping genes.
Normalized gene expression is depicted as relative expression to cells transfected with mimic-ctrl2. Values represent the mean of three biological
replicates (*** P ≤ 0.001, ** P ≤ 0.01, ns = non-significant compared to control, unpaired t test)
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addition, migration of MCF10A cells was reduced upon
knockdown of ITGA6 (Fig. 5c). The synergistic effect of
these two target genes might be a partly explanation for
the enhanced phenotype of the 5’isomiR in transwell mi-
gration on MCF10A cells when compared to MDA-MB-
231 (see Fig. 2c).
Discussion
IsomiR is a term coined to describe length and/or
sequence variations of the same miRNA. Different
mechanisms underlie the generation of isomiRs, stem-
ming usually from the normal biogenesis pathway of
miRNAs [34]. In the current work, we present the func-
tional characterization of 5’isomiR-140-3p, where the
phenotypes of different cell lines are examined upon the
overexpression of the 5’isomiR-140-3p in comparison to
the canonical hsa-miR-140-3p. TCGA breast cancer pa-
tients’ sequencing data revealed that the expression of
both isoforms is strongly positively correlated indicating
a stochastic post-transcriptional process leading to the
formation of both forms [48]. Additionally, a trend of
better survival among TNBC patients was observed with
higher expression levels of both hsa-miR-140-3p and
5’isomiR-140-3p. This might point to a possible syner-
gistic role of the canonical hsa-miR-140-3p and the
5’isomiR-140-3p in suppressing the growth or develop-
ment of breast cancer.
The tumor suppressor role for miR-140 has been char-
acterized and reported by Wolfson B et al., where they
showed that miR-140 acts by negatively regulating Wnt,
SOX2 and SOX9 [44]. The latter are known to be key
stem cell self-renewal regulatory elements. Inhibition of
miR-140 expression was found to be through an ER-
mediated mechanism and/or through differential methy-
lation of CpG islands in the miR-140 promoter region.
This results in uncontrolled elevation of SOX2, causing
an increase in stem cell populations and breast cancer
initiation, progression and growth [44, 49]. Based on
the hypothesis that canonical miRNAs and their func-
tional isomiRs might synergistically target related phe-
notypes, we were interested in assessing the effects of
overexpressing the hsa-miR-140-3p and its 5’isomiR on
different cancer-associated cellular phenotypes includ-
ing viability, cell cycle, and cellular migration.
We observed that, contrary to the effect of the canonical
hsa-miR-140-3p, overexpression of the 5’isomiR-140-3p
led to a decrease in cell viability. The latter observation
was supported by cell cycle analysis, where the 5’isomiR-
140-3p but not the hsa-miR-140-3p caused cell cycle ar-
rest in G0/G1 phase evident by 7-AAD/BrdU cell cycle
analysis. Co-transfection of the two forms did not result in
synergistic effects on cell viability in any of these three cell
lines (data not shown). Noteworthy, we found that the
5’isomiR downregulates a larger number of genes com-
pared to the canonical miRNA annotated in miRBase.
This corresponds to the observation, that the isomiR is
considered to be the canonical form in several species in-
cluding species closely related to humans such as gorilla.
We identified three novel direct target genes related
to the observed phenotypes: COL4A1, ITGA6 and
MARCKSL1. COL4A1 encodes for collagen, type IV,
alpha1. Type IV collagen is a main component of
basement membranes, where molecules attach to each
other forming complex protein networks. These
Fig. 4 Representation of the genes and 3’UTRs of the identified target
genes of 5’isomiR-140-3p, namely MARCKSL1 (a), COL4A1 (b) and ITGA6
(c). Nucleotides that were mutated for target validation presented in
Fig. 3c are highlighted
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networks help the basement membranes interact with
nearby cells, playing a role in cell movement or migra-
tion, cell survival and proliferation, and cell differenti-
ation [49]. We observed that knockdown of COL4A1
caused a slight reduction in cell viability, cell cycle ar-
rest in the G0/G1 phase and decrease in cellular mi-
gration through transwells. Previous studies pointed to
the effect of COL4A1 in tumor progression and metas-
tasis. Chen et al. observed a change in morphology of
the skin cancer cells upon knocking down the COL4A1
gene [50]. They also noted that knocking down
COL4A1 conferred the cells with higher levels of elasti-
city and lower motility.
ITGA6 is the gene encoding for the α6 subunit of
integrins and forms heterodimers preferentially with the
β4 and β1 subunits. Integrins are a group of proteins
that regulate the cell-cell adhesion as well as the cell-
matrix adhesion. They also transmit chemical signals
that modulate cell growth and can alter the activity of
certain genes [51]. Similar to COL4A1, we observed that
knockdown of ITGA6 caused a reduction in cell viability
and in MCF10A cells a decrease in cellular migration
through transwells. In the study of hepatocellular carcin-
oma (HCC), it was shown that Integrin α6 can mediate
metastasis, and that it could be used as a therapeutic tar-
get for improved patients’ survival. Knockdown of
Fig. 5 Effect of candidate genes knockdown on cell viability, cell cycle and cell migration. MCF10A and MDA-MB-231 cells were transfected with
candidate siRNAs (2 individual oligos for each target gene). siAllstar was used as negative controls. a Cells were incubated for 72 h, then WST-1
reagent was added and the absorbance was measured at 450 nm. Results were normalized to the negative control. COL4A1 and ITGA6 but not
MARCKSL1 knockdown was found to decrease cell viability. Data are presented as average of 6 biological replicates ± standard deviation indicated
as error bars. b 24 h after transfection starved in serum-free media for 24 h and allowed to re-enter the cell cycle for 24 h in full growth medium.
Cells were incubated with BrdU for 30 min before fixation and lysis and stained with anti-BrdU-FITC and 7-AAD for subsequent FACS analysis. Data
are presented as average and standard deviation of three biological replicates. c 48 h after transfection, cells were reseeded in transwell inserts
(with 8.0 μm polycarbonate membrane) in starvation medium. The lower well compartment had full growth medium to stimulate cell migration
across the insert membrane. After 20 h of migration, transwells were removed and cells were trypsinized from the lower surface of the membrane
and counted using flow cytometry (FACSCalibur). The absolute number of cells migrating was normalized to the total cell number and values
are presented as fraction of cells migrating. Values represent the average of 3 biological replicates ± standard deviation indicated as error bars
(* P ≤ 0.05 compared to control, t test)
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ITGA6 using shRNA was found to inhibit the prolifera-
tion and metastasis of HCC cells though PI3K/AKT and
MAPK/ERK, where p-ERK and p-AKT were reduced by
shRNA targeting integrin α6 [52]. The effects of 5’iso-
miR-140-3p overexpression on the signaling molecules
downstream of the collagen/Integrin signaling pathway
remain to be studied. Additionally, in esophageal squa-
mous cell carcinoma (ESCC), ITGA6 was found to be
highly expressed. In agreement with the results reported
in HCC, in vitro knockdown of ITGA6 in ESCC cells re-
sulted in inhibition of cell proliferation, invasion and col-
ony formation [53]. Given the tight connection between
integrins and collagens, their combinatorial downregula-
tion by the 5’isomiR might be a reason for the reduced mi-
gratory potential of cells overexpressing the 5’isomiR.
MARCKSL1 encodes for a member of the myristoy-
lated alanine-rich C- kinase substrate (MARCKS) family.
This family of proteins functions in cytoskeletal regula-
tion, protein kinase C signaling and calmodulin signal-
ing. MARCKSL1 protein affects the formation of the
intermediate junction (also called adherens junction or
belt desmosome), which is a type of cell-cell junctions
occurring in epithelial as well as endothelial cells [54, 55].
Our experiments revealed a significant reduction in cellu-
lar migration across the transwells upon the knockdown
ofMARCKSL1. Consistent with these results, Jonsdottir et
al. studied the prognostic value of MARCKSL1 in lymph
node-negative breast cancer patients. Among different
prognosticators studied (age, tumor diameter, grade, estro-
gen receptor, and proliferation), MARCKSL1 protein ex-
pression was the strongest prognosticator. Patients with
high MARCKSL1 expression showed a 44 % survival ver-
sus 88 % in patients with low expression at 15-year
follow-up. Moreover, distant metastasis free survival was
found to be significantly higher in patients with low
MARCKSL1 protein expression (78 %), compared to 45 %
survival for patients with high expression [56]. Addition-
ally, in a separate study that involved breast cancer metas-
tasis to the bone, MARCKSL1 was reported to be
upregulated. Björkblom et al. searched the In Silico Tran-
scriptomics (IST) database for MARCKSL1 expression
data. They found that in normal tissues, MARCKSL1
mRNA was highly expressed in the central nervous sys-
tem, testis, ovary, and lymphatic organs. In addition to
breast cancer, there was significant upregulation of
MARCKSL1 in lung cancer, rhabdomyosarcoma, leiomyo-
sarcoma, prostate cancer and uterine cancer [55].
Counter-intuitively, knockdown of MARCKSL1 in dif-
ferent tissue contexts, specifically the neural tissue, and
prostate cancer cell line (PC-3) resulted in an abrupt in-
crease in migration. This was explained by the fact that
activation of MARCKSL1 through phosphorylation leads
to its interaction with actin, reducing actin turnover in
cells and retarding cell migration [55]. Hence, it seems
to depend on the cellular context and the phosphoryl-
ation status of MARCKSL1 whether its downregulation
results in increased or decreased migration of the cells.
Conclusions
In conclusion, in this work we present the characterization
of 5’isomiR-140-3p. Its overexpression in breast cancer
cells resulted in phenotypes counteracting the progression
of cancer including reduction in cell viability, cell cycle ar-
rest and inhibition of migration. Moreover, we were able
to identify and validate novel targets for the 5’isomiR-140-
3p; COL4A1, ITGA6 and MARCKSL. Finally, we have
shown that knocking down these genes could partially
phenocopy the effects of the 5’isomiR-140-4p overexpres-
sion. COL4A1 and ITGA6 knockdown led to less cell via-
bility and cell cycle arrest, while MARCKSL1 knockdown
resulted in a decrease in the migratory potential of cells.
Figure 6 represents a summary of our understanding to
the regulation of the miR-140 expression and its targets.
This study shows – to our knowledge – the first ex-
ample on the functional discrepancy of the two highly
expressed isoforms a miRNA in the context of human
cancer. Despite the difference in their regulatory roles,
both the canonical miRNA and the 5’isomiR work in a
tumor suppressor direction. It’s worth mentioning that
the mechanism underlying the regulation of the canonical
or the 5’isomiR expression is not yet fully understood.
Interestingly, we found that the ratio of the canonical
miRNA and the 5’isomiR was significantly shifted towards
to canonical form when comparing normal breast tissue
with breast cancer tissue data, both from the TCGA data-
set. An open question to be asked here is whether and
how the cell can decide for or control which variant of the
miRNA to express at which circumstances.
Lastly, with isomiRs in picture, the study of miR-
NAome is way more complex than previously thought.
A growing number of reports point to the biological
significance of at least some isomiRs. One nucleotide
shift changes the spectrum of targeted genes, changing
thereby the functional regulatory role of the miRNA.
Through further characterization of the canonical miR-
140-3p and the 5’ismoiR-140-3p and other miRNA/
5’isomiR pairs, more insights will be gained into the
carcinogenesis of breast cancers. This will potentially
provide one more tool to be used by clinicians in diag-
nosis or treatment.
Methods
Cell culture and reagents
MCF10A, MDA-MB-231, MDA-MB-468 and MCF-7 cell
lines were obtained from ATCC (Manassas, VA, USA) in
2009 and 2010. Cell lines were verified using the cell line
authentication service at the DKFZ Core Facility by Multi-
plex human cell authentication in 2011 (23). Cells were
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incubated in a humidified incubator at 37 °C and 5 % CO2.
MCF10A cells were cultured in DMEM F12 medium (5 %
Horse serum, 20 ng/ml EGF (BD Biosciences, Bedford,
MA, USA), 0.5 μg/ml Hydrocortisone (Sigma-Aldrich,
Saint-Louis, MO, USA), 100 ng/ml Choleratoxin (Sigma-
Aldrich, Saint-Louis, MO, USA), 0.01 mg/ml bovine insulin
(Sigma-Aldrich, Saint-Louis, MO, USA), 50 units/ml peni-
cillin, 50 μg/ml streptomycin sulfate). MDA-MB-231 and
MDA-MB-468 cells were maintained in RPMI1640
medium (10 % FBS, 1 % L-glutamine, 1 % nonessential
amino acids, 50 units/ml penicillin, 50 μg/ml streptomycin
sulfate). MCF-7 cells were cultured in MEM medium (10 %
FBS, 1 % nonessential amino acids, 1 % L-glutamine, 50
units/ml penicillin, 50 μg/ml streptomycin sulfate). Cell cul-
ture media and reagents were obtained from Invitrogen.
Transfections
All transfections were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s
protocol. miRNA mimics were purchased from Ambion
(Life technologies). The mature sequences for hsa-miR-
140-3p and 5’isomiR-140-3p are 5’UACCACAGGGUAG
AACCACGG 3’ and 5’ ACCACAGGGUAGAACCACG
GAC 3’ respectively. miRNA negative controls were ob-
tained from Dharmacon (Lafayette, CO). siRNAs against
COL4A1, ITGA6, and MARCKSL1 were purchased from
Dharmacon as set of four individual siRNAs per gene.
Two of them were used for phenotypic analyses. siAll-
Star non-targeting control was obtained from Qiagen
(Hilden, Germany). siRNAs and miRNA mimics were
used at a final concentration of 30 nM.
Microarray-based analysis of deregulated genes
MCF10A and MDA-MB-231 cells were seeded in 6-well
plates and transfected with miRNA mimics for hsa-miR-
140-3p and 5’isomiR-140-3p in two biological replicates,
each, as well as with one replicate of mimic-ctrl1 and
mimic-ctrl2. 48 h after transfection, RNA was extracted
Fig. 6 Schematic diagram summarizing the role of the miR-140 in the course of breast cancer development. miR-140 expression is inhibited by
the action of estrogen receptor or through differential methylation of CpG islands in its promoter region. Upon its expression, two different
isoforms are formed that act synergistically to suppress the growth and development of breast cancer. The canonical hsa-miR-140-3p acts by
negatively regulating the Wnt, SOX2 and SOX9 [44]. The latter are known to be key stem cell self-renewal regulatory elements. Inhibition of
miR-140 expression results in uncontrolled elevation of SOX2, causing an increase in stem cell populations and breast cancer initiation,
progression and growth. The 5’isomiR-140-3p acts by reducing cellular viability, cellular migration and arresting the cell cycle in the G0/G1
phase through targeting COL4A1, ITGA6, and MARCKSL1
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using the RNeasy kit (Qiagen, Hilden, Germany) and
submitted to the Microarray unit of the Genomics-
Proteomics Core Facility of the German Cancer Research
Center. Genes were considered to be downregulated by
the canonical miRNA or the 5’isomiR, respectively, if they
showed an expression of less than 65 % of the expression
in control transfected cells and the corrected p-value was
below 0.05. Results from the microarray were uploaded to
GEO (GSE74539).
Luciferase reporter assays
To validate direct targeting of miRNAs, 100 ng/well psi-
CHECK2 vectors (Promega, Madison, WI, USA), con-
taining the respective 3’UTRs, were co-transfected with
mimic miRNAs in MCF-7 cells. 48 h after transfection
Renilla and firefly luciferase activities were determined
as previously described using a luminometer (Tecan, Linz,
Austria) [57]. Mutations within each of the predicted tar-
get sites of the 3’-UTRs were generated by site-directed
mutagenesis using Quikchange Lightning kit (Aglient
Techonologies). Primers are listed in Additional file 6.
RNA isolation and real-time PCR
Total RNA was isolated from cells using the RNeasy
mini kit (Qiagen) according to the manufacturer’s in-
structions. Reverse transcription of mRNAs into cDNA
was done using the Transcriptor Reverse Transcriptase
kit (Roche). The qRT-PCR reactions for target genes
were performed using the ABI Prism 7900HT sequence
detection system (Applied Biosystems, Weiterstadt,
Germany), using probes from the Universal Probe Li-
brary (Roche Diagnostics). For normalization of the
mRNA analysis, HPRT1 and GAPDH were used as
housekeeping genes.
WST-1 based cell viability assay
5 × 103 MCF-10A, MDA-MB-468 or MDA-MB-231
cells/well were seeded into 96-well plates. After 24 h,
cells were transfected with the respective miRNAs or
siRNAs. Transfections were performed in 6 replicates.
72 h later, 10 μL/well WST-1 reagent were added and
the absorbance of the plate was measured at 450 nm
using the TECAN plate reader (Infinite® M200). As
medium blank, 10 μL of WST-1 reagent was added to a
well containing only medium without cells and the ab-
sorbance of this well was subtracted from all other
values obtained.
Cell cycle analysis
Cells were seeded as a single cell suspension with 1.5 × 105
cells/well into 6-well plates and transfected as described
above. 48 h after transfection, the cells were incubated
with BrdU for 30 min before fixation with Cytofix/Cyto-
perm (BD Biosciences, Heidelberg, Germany) according to
the manufacturer’s recommendations. BrdU was stained
with a FITC-conjugated anti-BrdU antibody (BD Biosci-
ences, Heidelberg, Germany) and DNA was stained with
7-AAD. Samples were analyzed using a FACSCalibur
(Becton-Dickenson) and their distributions in the distinct
cell cycle phases G0/G1, S and G2/M phases was assessed
based on their fluorescence intensity for both dyes.
Transwell-based cell migration assay
MCF10A cells were transfected with 30 nM siRNAs or
miRNAs in 6-well plates as described above. 48 h after
transfection, cells were detached and 2 × 105 cells were
seeded in starvation medium into transwell inserts with
8.0 μm pore-sized membranes in the 24-well plates for-
mat (Corning). Full growth medium was used as chemo-
attractant in the lower chamber. To control for the
number of cells, cells from the same suspension were
seeded into poly-L-lysine coated 0.72 μm glass bottom
square well MatriPlates. After 6 h (to allow for cell at-
tachment), cells were stained with Hoechst-33258 and
counted using Olympus ScanR microscope. In the trans-
wells, cells were allowed to migrate for 20 h and the
number of migrating cells was determined by flow cy-
tometry using a FACSCalibur (Becton-Dickenson). For
that purpose, cells attached to the lower side of the
membrane were trypsinized and transferred into FACS-
tubes. Cells were centrifuged, washed once with PBS and
resuspended in 150 μl PBS. Cells were counted for a
total of 2 min at high flow rate. The number of cells mi-
grating was normalized to the total cell number from
the counting control and values were presented as frac-
tion of cells migrating.
Analysis of small RNA sequencing of breast cancer cell
lines
Small RNA sequencing data distributed during the Illu-
mina iDEA challenge was submitted to ArrayExpress
(E-MTAB-4539) with kind permission by Illumina; de-
tails on the experimental setup can be found in the re-
spective metadata. Briefly, the data had been generated
by Illumina on a Gene Analyzer instrument using total
RNA from eight commonly used breast cancer cell lines.
Adapters were trimmed using trimmomatic and bowtie
was used for mapping of the sequences to the genome
(GRCh38) without allowing for any mismatches. IsomiR
notation was based on miRBase version 21 and reads were
mapped to the specific isomiR using bedtools intersect.
We analyzed the data for the presence of highly abun-
dant miRNAs with associated highly abundant 5’isomiRs
using an average expression over all cell lines of
100 rpm and a ratio of isomiR to miR of at least 1:5 as
threshold to define potentially interesting pairs.
To do so, we did not distinguish variants at the 3’end
of both species, treating all 3’isomiRs with a length of
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18-24 nucleotides as miRNA or 5’isomiR, respectively,
depending on their 5’ end. Using the notation suggested
by Loher and colleagues [27], we refer for example to all
miRNA species between hsa-miR-140-3p 0|-3 and 0| + 3
(in Table 1 simplified as 0|x) as canonical hsa-miR-140-
3p, whereas all species between hsa-miR-140-3p +1|-2
to +1| + 3 (in Table 1 simplified as +1|x) are considered
as 5’isomiR-140-3p.
Patient data analyses
Expression values of hsa-miR-140-3p and the 5’isomiR-
140-3p were extracted from the TCGA breast cancer
dataset (accessed August 2013) and correlated with clin-
ical parameters such as ER- or metastasis status [46].
The reads for miR and isomiR as well as the clinical pa-
rameters are provided as Additional file 2. Survival ana-
lyses were performed using GraphPad Prism verson 6.0;
the upper and the lower quartiles of expression were
considered as ‘high’ and ‘low’, respectively.
Statistical analyses
Data are presented as mean ± S.D. Samples were analyzed
by two-tailed unpaired Student’s t test, unless otherwise
mentioned, and p values < 0.05 were considered as being
statistically significant. p values < 0.05, < 0.01, and < 0.001
are indicated with one, two, and three asterisks, respect-
ively. Data obtained from breast cancer patient samples
were analyzed using GraphPad Prism verson 6.0.
Additional files
Additional file 1: miRNA seq dataset used to identify highly abundant
miRNAs that have abundant 5’isomiRs. (XLSX 3320 kb)
Additional file 2: Clinical data and miR/isomiR expression of patients
from the TCGA breast cancer cohort [48]. (XLS 7116 kb)
Additional file 3: Relative abundance of 3’isomiRs of miR-140-3p and
5’isomiR-140-3p in the TCGA breast cancer patient cohort. The table lists
the genomic coordinates, the notation of the isomiR and the average
expression of each individual form (in rpm). (XLSX 9 kb)
Additional file 4: Genes deregulated by hsa-miR-140-3p, 5’isomiR-140-
3p or both in both MCF10A and MDA-MB-231 cells. This table contains
the genes which are downregulated in both cell lines by either hsa-miR-
140-3p, 5’isomiR-140-3p or both by at least 35 % and with a significant
corrected p-value. These genes are summarized in the Venn diagram in
Fig. 2a. In addition, the genes that are upregulated in both cell lines by
at least 65 % and with a significant corrected p-value by either has-miR-
140-3p, 5’isomiR-140-3p or both are also listed in this table. Values are
reported as log2 fold changes and Benjamini-Hochberg corrected
p-values. (XLS 74 kb)
Additional file 5: Venn Diagrams of predicted and downregulated
genes for both miRNA species. Predicted targets according to TargetScan
irrespective of site conservation and downregulated genes as listed in
Additional file 3 for miR-140-3p (A) and 5’isomiR-140-3p (B) are depicted.
For both miRNA species, downregulated genes are significantly enriched
for predicted targets of the respective miRNA (p < 0.001 as determined
by Chi-square test). (JPG 62 kb)
Additional file 6: List of primers and probes. This file contains all
primer sequences used for cloning and mutagenesis of the luciferase
reporter plasmids, as well as the UPL primers and probes used for qRT-
PCR. (DOCX 17 kb)
Additional file 7: Efficiency of target gene knockdown on the mRNA
level using Taqman qRT-PCR. MCF10A cells were transfected with different
siRNAs or siRNA negative control (siAllstar). 72 h later, cells were lysed
and total mRNA was isolated and purified using RNeasy kit (Qiagen).
The mRNA expression levels of the candidate genes were then assessed
by Taqman qRT-PCR. Gene expression was normalized to HPRT and
GAPDH housekeeping genes. Normalized gene expression is depicted
as relative expression to cells transfected with siAllstar. Values represent
the mean of three technical replicates. (JPG 350 kb)
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